Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Esophageal or Head and Neck Squamous Cell Carcinomas
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety and feasibility of anti-programmed cell
death protein 1(PD-1) immunotherapy, Camrelizumab, combined with cyclin-dependent kinase 4/6
blockade, Dalpiciclib, as a new neoadjuvant treatment regimen for patients with resectable
esophageal squamous cell carcinoma (ESCC) or or head and neck squamous cell carcinoma(HNSCC).